So far, China has made no official public threat about weaponizing its dominant position in this segment of the ...

These schemes are aimed at protecting and encouraging domestic ingredient manufacturing which is seen as a critical step in ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...

India's pharma sector is at a turning point as the government seeks to strengthen local manufacturing through an upgraded ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

Instead of battling over tariffs, Washington and Beijing have turned to a potentially far more harmful strategy: flexing ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

US President Donald Trump on May 23 threatened to impose a 50 percent tariff on all imports from the European Union.

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance generating revenues with ensuring that a new medicine reaches the largest possible ...